Riffyn has partnered with Imperial College London to build digital foundations for accelerating synthetic biology research. Through this partnership, Riffyn Nexus will be available to all IC students and will be introduced to entrepreneurs at the London Biofoundry.
Amidst the early COVID-19 chaos — when most of us were still in denial about the virus — two visionaries at Imperial College London started developing a new kind of COVID-19 test. Fully automated, scalable to thousands of tests per day, and reagent agnostic, the test workflow was developed, validated, and rolled out by the U.K. National Health Service to test 1,000 patient samples per day in only 9 weeks. Here's how they did it - and why the driving principles behind biofoundries and the advanced capabilities of Riffyn Nexus and other "lab of the future" systems were critical to their success.
Follow Riffyn on our journey to help R&D teams discover more.
Thank you for subscribing. We look forward to communicating in the future.
Novozymes delivers four break-through biofuels products to market in half the normal development time with transformative digital infrastructure.Get the case study